|
Dr. Watanabe was formerly a senior executive at Eli Lilly & Company, where he occupied the positions of Executive Vice President of Science and Technology, President of Lilly Research Laboratories and a member of the Board of Directors. During his tenure the company became recognized as having one the strongest new drug pipelines in the industry, including Forteo® and Xigris® and the recently launched drugs Alimta®, Cialis®, Cymbalta® and Straterra®. From 1971 to 1990, Dr. Watanabe was a full time faculty member at Indiana University School of Medicine. He was professor and chairman of the department of medicine at the medical school from 1983 to 1990. Dr. Watanabe was also formerly a director of the American Heart Association and the American College of Cardiology, and a member of the American Society of Clinical Investigation and the Association of American Physicians. He served for six years as chairman of the Science and Technology Section of the Pharmaceutical Research and Manufacturing Association of America (PhRMA). Dr. Watanabe is a partner in Twilight Venture Partners LLC and serves as Volunteer Chairman of BioCrossroads, Indiana's leading public-private life science network. He also serves as a director of Guidant Corporation, the Indiana University Foundation and the Damon Runyon Cancer Research Foundation. | 